These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3281 related articles for article (PubMed ID: 21612468)
1. Abiraterone and increased survival in metastatic prostate cancer. de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI; N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468 [TBL] [Abstract][Full Text] [Related]
2. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231 [TBL] [Abstract][Full Text] [Related]
3. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; De Porre P; Kheoh T; Park YC; Todd MB; Chi KN; N Engl J Med; 2017 Jul; 377(4):352-360. PubMed ID: 28578607 [TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Fizazi K; Scher HI; Molina A; Logothetis CJ; Chi KN; Jones RJ; Staffurth JN; North S; Vogelzang NJ; Saad F; Mainwaring P; Harland S; Goodman OB; Sternberg CN; Li JH; Kheoh T; Haqq CM; de Bono JS; Lancet Oncol; 2012 Oct; 13(10):983-92. PubMed ID: 22995653 [TBL] [Abstract][Full Text] [Related]
5. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059 [TBL] [Abstract][Full Text] [Related]
6. Abiraterone in metastatic prostate cancer without previous chemotherapy. Ryan CJ; Smith MR; de Bono JS; Molina A; Logothetis CJ; de Souza P; Fizazi K; Mainwaring P; Piulats JM; Ng S; Carles J; Mulders PF; Basch E; Small EJ; Saad F; Schrijvers D; Van Poppel H; Mukherjee SD; Suttmann H; Gerritsen WR; Flaig TW; George DJ; Yu EY; Efstathiou E; Pantuck A; Winquist E; Higano CS; Taplin ME; Park Y; Kheoh T; Griffin T; Scher HI; Rathkopf DE; N Engl J Med; 2013 Jan; 368(2):138-48. PubMed ID: 23228172 [TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE; Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341 [TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ; Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659 [TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939 [TBL] [Abstract][Full Text] [Related]
11. Abiraterone and increased survival in metastatic prostate cancer. Berruti A; Pia A; Terzolo M N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182 [No Abstract] [Full Text] [Related]
12. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830 [TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
20. Commentary on "Abiraterone in metastatic prostate cancer without previous chemotherapy." Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. N Engl J Med 2013;368(2):138-48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584. Trump DL Urol Oncol; 2013 Nov; 31(8):1846. PubMed ID: 24210085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]